KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Debt: 2009-2024

Historic Total Debt for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $51.9 million.

  • Ionis Pharmaceuticals' Total Debt rose 1318.83% to $630.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.9 million, marking a year-over-year increase of 1318.83%. This contributed to the annual value of $51.9 million for FY2024, which is 39.74% down from last year.
  • Ionis Pharmaceuticals' Total Debt amounted to $51.9 million in FY2024, which was down 39.74% from $86.2 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Total Debt peaked at $368.8 million during FY2020, and registered a low of $16.0 million during FY2022.
  • Its 3-year average for Total Debt is $51.4 million, with a median of $51.9 million in 2024.
  • In the last 5 years, Ionis Pharmaceuticals' Total Debt surged by 495.41% in 2020 and then plummeted by 82.85% in 2021.
  • Ionis Pharmaceuticals' Total Debt (Yearly) stood at $368.8 million in 2020, then plummeted by 82.85% to $63.2 million in 2021, then tumbled by 74.74% to $16.0 million in 2022, then skyrocketed by 439.46% to $86.2 million in 2023, then tumbled by 39.74% to $51.9 million in 2024.